NEKTAR THERAPEUTICS (NKTR) 2.59 -0.02 (-0.77%)
2.59 -0.02 (-0.77%)
US6402681083 - Common Stock
Buy % Consensus
Analysts have set a mean price target of 4.5. This target is 73.85% above the current price.
NKTR was analyzed by 15 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about NKTR.
In the previous month the buy percentage consensus was at a similar level.
NKTR was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-08-08 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-04-18 | Mizuho | Maintains | Neutral |
| 2022-04-18 | SVB Leerink | Maintains | Market Perform |
| 2022-04-18 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2022-03-09 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2021-11-08 | Benchmark | Upgrade | Hold -> Buy |
| 2021-11-08 | SVB Leerink | Maintains | Market Perform |
| 2021-11-05 | Oppenheimer | Maintains | Perform |
| 2021-09-10 | B of A Securities | Initiate | Neutral |
| 2021-08-06 | SVB Leerink | Maintains | Market Perform |
| 2021-06-28 | Stifel | Upgrade | Hold -> Buy |
| 2021-05-10 | SVB Leerink | Maintains | Market Perform |
| 2021-04-06 | SVB Leerink | Maintains | Market Perform |
| 2021-02-22 | Benchmark | Downgrade | Buy -> Hold |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA